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Classical benzodiazepines (BZs) exert anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive, and amnesic effects through
potentiation of neurotransmission at GABAA receptors containing a1, a2, a3 or a5 subunits. Genetic studies suggest that modulation at
the a1 subunit contributes to much of the adverse effects of BZs, most notably sedation, ataxia, and amnesia. Hence, BZ site ligands
functionally inactive at GABAA receptors containing the a1 subunit are considered to be promising leads for novel, anxioselective
anxiolytics devoid of sedative properties. In pursuing this approach, we used two-electrode voltage clamp experiments in Xenopus
oocytes expressing recombinant GABAA receptor subtypes to investigate functional selectivity of three newly synthesized BZ site ligands
and also compared their in vivo behavioral profiles. The compounds were functionally selective for a2-, a3-, and a5-containing subtypes of
GABAA receptors (SH-053-S-CH3 and SH-053-S-CH3-2
0F) or essentially selective for a5 subtypes (SH-053-R-CH3). Possible influences
on behavioral measures were tested in the elevated plus maze, spontaneous locomotor activity, and rotarod test, which are considered
primarily predictive of the anxiolytic, sedative, and ataxic influence of BZs, respectively. The results confirmed the substantially diminished
ataxic potential of BZ site agonists devoid of a1 subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of SH-053-S-
CH3 and SH-053-S-CH3-20F. However, all three ligands, dosed at 30 mg/kg, decreased spontaneous locomotor activity, suggesting that
sedation may be partly dependent on activity mediated by a5-containing GABAA receptors. Hence, it could be of importance to avoid
substantial agonist activity at a5 receptors by candidate anxioselective anxiolytics, if clinical sedation is to be avoided.
Neuropsychopharmacology (2008) 33, 332–339; doi:10.1038/sj.npp.1301403; published online 28 March 2007
























































Since their clinical introduction in the early 1960s,
benzodiazepines (BZs) have been extensively prescribed
worldwide to cope with anxiety, insomnia, muscle spasms,
and epilepsy. The basic characterization of the diverse
pharmacological effects of BZs: anxiolytic, sedative, hypno-
tic, muscle relaxant, anticonvulsive, and amnesic, has
been considered to represent one of the major successes
of behavioral pharmacology (Sanger et al, 2003). In recent
years, much effort has been expended to improve the
understanding of the molecular and neuronal substrates of
these effects, with the final goal to clinically separate wanted
from unwanted effects (Sieghart and Sperk, 2002). Among
the latter effects, psychomotor and cognitive impairments
are common, and more serious neuropsychiatric reactions
such as amnesic and aggressive episodes may occur
(Lader, 1999).
BZs act as facilitators of fast inhibitory neurotransmission
in the mammalian brain mediated through GABAA recep-
tors, which are involved in the regulation of vigilance,
anxiety, muscle tension, epileptogenic activity, and memory
functions (Rudolph and Mo¨hler, 2004). The vast majority of
GABAA receptors are associations of two a subunits, two b
subunits, and a single g subunit, which form a central ion
channel, and approximately 80% of all GABAA receptors
contain a BZ-binding site located at the interface of the
g2 subunit and the respective a subunit (a1, a2, a3 or a5)
(Chang et al, 1996; Sigel and Buhr, 1997). It has been
postulated that the four BZ site-building a subunits, with
their distinct patterns of anatomical distribution in the
brain, participate differently in the various effects of BZs.
Indeed, recent genetic and pharmacological studies pointed
to the specific contribution of individual receptor sub-
types to the spectrum of behavioral actions of BZ site
ligands. Specifically, sedative effects of BZs were principally
attributed to a1-containing GABAA receptor subtypes,
anxiolytic actions to the a2-/a3-containing receptors, antero-
grade amnesic effects to the a1/a5 subtypes, anticonvulsant
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activity partially to the a1-containing receptors, and muscle
relaxant effects largely to a2-containing receptors (Atack
et al, 2006a; Low et al, 2000; McKernan et al, 2000; Rudolph
and Mo¨hler, 2006; Rudolph et al, 1999). Moreover, it
appears that L-838417, a ligand with zero efficacy at the a1
subtype, is unable to engender sedation in rodents
(McKernan et al, 2000) or monkeys (Rowlett et al, 2005),
and similar conclusions were drawn from behavioral
experiments with other compounds functionally selective
for receptors other than a1-containing receptors (Atack
et al, 2006c; Dias et al, 2005; Licata et al, 2005). Since the
a1-subunit is critically involved in much of the unwanted
psychomotor activity of nonselective BZs, ‘a1-neutral’
agonists at BZ site are being pursued in the quest for
anxioselective anxiolytics (Basile et al, 2004; Whiting, 2006).
To date, all apparently non-sedating BZ site ligands,
which are devoid of activity at a1-containing GABAA
receptors, engendered essentially antagonist (Atack et al,
2006c; Dias et al, 2005) or only partial agonist efficacy at a5-
containing GABAA receptors (Griebel et al, 2001; McKernan
et al, 2000). Therefore, it cannot be ruled out that
substantial efficacy at a5-containing GABAA receptors may
contribute to sedative effects. This is supported by data,
which indicate the possibility of substantial motor influence
by modulation of a5 subunit containing GABAA receptors.
In the spinal cord, somatic and preganglionic motoneurons
(lamina IX and lateral cell column) exhibited a moderate to
strong staining for the a5 subunit (Bohlhalter et al, 1996).
Knock-in mice with the GABAA receptor a5 subunit
rendered insensitive to diazepam were refractory to
development of tolerance to the sedative effect of diazepam
dosed subchronically (van Rijnsoever et al, 2004). These
two sets of evidence indicate that the motor influence of a5-
GABAA receptor modulation, if present, is not necessarily
an indirect consequence of the established effects on
learning and memory processes (Collinson et al, 2002;
Crestani et al, 2002). Hence, any activity changes seen with
ligands possessing a substantial agonistic efficacy for a5
subunit containing GABAA receptors may be, at least partly,
mediated by such receptors.
To test this hypothesis, we identified such ligands by
using two-electrode voltage clamp experiments in Xenopus
oocytes expressing recombinant GABAA receptor subtypes.
Three newly synthesized BZ site ligands turned out to be
functionally selective for a2, a3, and a5 subtypes of GABAA
receptors (SH-053-S-CH3 and SH-053-S-CH3-20F), or essen-
tially selective for the a5 subtypes (SH-053-R-CH3). We then
compared their in vivo behavioral profiles with that of the
classical nonselective agonist diazepam. Possible influences
on behavioral measures were tested in the elevated plus
maze (EPM), spontaneous locomotor activity (SLA) and
rotarod test that are considered primarily predictive of the
anxiolytic, sedative and ataxic influence of BZs, respectively.
MATERIALS AND METHODS
Drugs
SH-053-S-CH3 and SH-053-R-CH3 (the (S) and (R) stereo-
isomer, respectively, of 8-ethynyl-4-methyl-6-phenyl-4H-2,
5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester;
structures given in Figure 1) as well as SH-053-S-CH3-20F
(the (S) stereoisomer of 8-ethynyl-6-(2-fluorophenyl)-
4-methyl-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic
acid ethyl ester) were synthesized at the Department of
Chemistry and Biochemistry, University of Wisconsin-
Milwaukee. Diazepam for behavioral studies was obtained
from Galenika (Belgrade, Serbia).
Electrophysiological Experiments
Cloning of GABAA receptor subunits a1, b3, and g2 into
pCDM8 expression vectors (Invitrogen, CA) has been
described elsewhere (Fuchs et al, 1995). cDNAs for subunits
a2, a3, and a5 were gifts from P Malherbe and were
subcloned into pCI vector. After linearizing the cDNA
vectors with appropriate restriction endonucleases, capped
transcripts were produced using the mMessage mMachine
T7 transcription kit (Ambion, TX). The capped transcripts
were polyadenylated using yeast poly(A) polymerase (USB,
OH) and were diluted and stored in diethylpyrocarbonate-
treated water at 701C.
The methods used for isolating, culturing, injecting, and
defolliculating of the oocytes were identical as described
previously (Sigel, 1987; Sigel et al, 1990). Briefly, mature
female Xenopus laevis (Nasco, WI) were anesthetized in a
bath of ice-cold 0.17% Tricain (Ethyl-m-aminobenzoat,
Sigma, MO) before decapitation and removal of the frog’s
ovary. Stage 5–6 oocytes with the follicle cell layer around
them were singled out of the ovary using a platinum
wire loop. Oocytes were stored and incubated at 181C in
modified Barths’ medium (MB, containing 88 mM NaCl,
10 mM HEPES-NaOH (pH 7.4), 2.4 mM NaHCO3, 1 mM KCl,
0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM Ca(NO3)2) that
was supplemented with 100 U/ml penicillin and 100 mg/ml
Figure 1 Structures and conformations of SH-053-S-CH3 (a1–a3) and
SH-053-R-CH3 (b1–b3). The molecular modeling was carried out as
described in Zhang et al (1995) and He et al (2000), and will not be
reiterated here. SH-053-S-CH3 fits the pharmacophore within the included
volume of the a2 subtype (a2); (a3) is the same image rotated 901. It can
be clearly seen that this conformer fits within the included volume. At (b2)
SH-053-R-CH3 fits the pharmacophore in the included volume of the a2
subtype; (b3) is the same image rotated 901. The R-CH3 at the prochiral
center C4 changes the conformation of the molecule causing the pendant
6-phenyl to stick outside the included volume; consequently, this ligand is
not efficacious at the a2 subtype. It simply does not interact strongly with
a1, a2, or a3 subtypes.
Benzodiazepine sedation and GABAA receptor a5 subunit
MM Savic´ et al
333
Neuropsychopharmacology
streptomycin. Oocytes with follicle cell layers still around
them were injected with a total of 2.25 ng of cRNA. cRNA
ratio used was 1 : 1 : 5 for the a subunits, b3, and g2,
respectively. After injection of cRNA, oocytes were incu-
bated for at least 36h before the enveloping follicle cell
layers were removed. To this end, oocytes were incubated
for 20 min at 371C in MB that contained 1 mg/ml
collagenase type IA and 0.1 mg/ml trypsin inhibitor I-S
(both Sigma). This was followed by osmotic shrinkage of the
oocytes in doubly concentrated MB medium supplied with
4 mM Na-EGTA and manually removing the follicle cell
layer. After peeling off the follicle cell layer, the cells were
allowed to recover overnight before being used in electro-
physiological experiments.
For electrophysiological recordings, oocytes were placed
on a nylon grid in a bath of Xenopus Ringer solution (XR,
containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4),
1 mM MgCl2, 1 mM KCl, and 1 mM CaCl2). The oocytes were
constantly washed by a flow of 6 ml/min XR, which could be
switched to XR containing GABA and/or drugs. Drugs were
diluted into XR from dimethylsulfoxide (DMSO) solutions
resulting in a final concentration of 0.1% DMSO perfusing
the oocytes. Drugs were preapplied for 30 s before the
addition of GABA, which was coapplied with the drugs until
a peak response was observed. Between two applications,
oocytes were washed in XR for up to 15 min to ensure full
recovery from desensitization. For current measurements,
the oocytes were impaled with two microelectrodes (2–
3 mO), which were filled with 2 mM KCl. All recordings
were performed at room temperature at a holding potential
of 60 mV using a Warner OC-725C two-electrode voltage
clamp (Warner Instruments, Hamden, CT). Data were
digitized, recorded, and measured using a Digidata 1322A
data acquisition system (Axon Instruments, Union City,
CA). Results of concentration response experiments were
graphed using GraphPad Prism 4.00 (GraphPad Software,
San Diego, CA). Data were graphed as mean7SEM of at
least four oocytes from at least two batches.
Behavioral Experiments
Experiments were carried out on male Wistar rats (Military
Farm, Belgrade, Serbia), weighing 200–240 g. All procedures
in the study conformed to EEC Directive 86/609 and were
approved by the Ethical Committee on Animal Experimen-
tation of the Medical Faculty in Belgrade. The rats were
housed in transparent plastic cages, six animals per cage,
and had free access to pelleted food and tap water. The
temperature of the animal room was 22711C, the relative
humidity 40–70%, the illumination 120 lux, and the 12/12 h
light/dark period (light on at 06:00). All handling and
testing took place during the light phase of the diurnal
cycle. Throughout the study the animals were used only
once. All drugs were dissolved/suspended with the aid of
sonication in a solvent containing 85% distilled water, 14%
propylene glycol, and 1% Tween 80, and were administered
intraperitoneally in a volume of 1 ml/kg.
Behavior on the Elevated Plus Maze
The apparatus was constructed of sheet metal, with a black
rubber floor. It consisted of a maze elevated to a height of
50 cm with two open (50 10 cm) and two enclosed arms
(50 10 40 cm), connected by a junction area (central
platform) measured 10 10 cm. A ledge of sheet metal
(0.3 cm high) surrounding the open arms was added. The
illumination in the experimental room consisted of one red
neon tube fixed on the ceiling, giving light intensity of
10 lux on the surface of the arms.
The animals were tested 20 min after injection of drugs
or solvent. At the beginning of the experiment, single rats
were placed in the center of the maze, facing one of the
enclosed arms, and their behavior was recorded for 5 min.
A digital camera was mounted above the maze and the
image was transmitted to a notebook computer in the
neighboring room, running the ANY-maze Video Tracking
System software (Stoelting Co., Wood Dale, IL, USA).
An entry into an open or closed arm was scored when
90% of the animal crossed the virtual line separating the
central square of the maze from the arm, whereas an exit
occurred when more than 90% of the animal left the
respective arm. After each trial, the maze was cleaned with
dry and wet towels.
Measurement of Locomotor Activity
Immediately after receiving the appropriate treatment,
single rats were placed in a clear Plexiglas chamber
(40 25 35 cm). Activity under dim red light (20 lux)
was recorded for a total of 45 min, without any habituation
period, using ANY-maze software (as described above). For
purposes of improving data analysis, the central 20% of the
chamber (200 cm2) was virtually set as a central zone. The
minimum percentage of animal that must have been in
the zone for an entry to occur was set at 70%, and 50% of
the animal must have remained in the zone for an exit not
to occur.
Rotarod Performance
Rotarod test (Ugo Basile, Comerio, Italy) measured the
capacity of the animal to maintain itself on the rod
revolving 10 r.p.m. During two consecutive days, the rats
were trained to walk on the revolving rod until they could
complete three 180 s sessions (each day) without falling of.
In the morning of the third day, the final selection was
made. Only animals capable of remaining 180 s on the rod,
without any fall, were chosen for further testing. The
animals which were not able to remain on the rod for 180 s
when tested 20 min after treatment were considered
incapacitated.
Statistical Analysis
All numerical data presented in the figures were given as
the mean7SEM. For electrophysiological data Student’s
t-test was used. Data from the EPM and activity assay
were assessed by a one-way ANOVA. If the ANOVA was
significant, each treatment condition was compared with
control by a Dunnett’s test (a¼ 0.05). ED50 value for rotarod
incapacitation was calculated by probit analysis according
to the method of Litchfield and Wilcoxon. Statistical
analyses were performed with ANY-maze software.
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In vitro data for SH-053-S-CH3 (Figure 2a) and SH-053-R-
CH3 (Figure 2b) demonstrated that at concentrations up to
1 mM both ligands significantly and dose-dependently
stimulated GABA EC3 response of a5-containing receptors
up to 300 and 200% of control current, respectively. These
compounds, thus, are high-efficacy agonists at the a5-
containing GABAA receptors comparable to diazepam (see
legend to Figure 2), with very low efficacies at a1 containing
subtypes. However, although SH-053-S-CH3 exerted sub-
stantial potentiation of an EC3 GABA response at a2 and
a3-containing GABAA receptors, the influence of SH-053-R-
CH3 at these receptors was comparable to its minor effect
at the a1 subtype (cf. molecular modeling in Figure 1). The
in vitro concentration–effect curves for SH-053-S-CH3-20F
(Rowlett JK, Furtmu¨ller R, Cook JM, unpublished results)
were similar to those for SH-053-S-CH3, but with a
higher magnitude of efficacies at the respective a2, a3,
and a5 GABAA receptor subtypes in the concentration range
0.1–10 mM.
Elevated Plus Maze
SH-053-S-CH3. Activity-related parameters: The influence
of treatment on closed arm entries did not reach statistical
significance (F(4,27)¼ 1.19, p¼ 0.337); statistical analysis
by ANOVA showed a significant effect of treatment neither
on total arm entries (F(4,27)¼ 1.72, p¼ 0.175) nor on total
distance travelled (F(4,27)¼ 1.80, p¼ 0.157).
Anxiety-related parameters (Figure 3): There was a close
to significant effect of treatment on distance travelled
in open arms (F(4,27)¼ 2.37, p¼ 0.078) (Figure 3a). The
overall influence of treatment on the percentage of
open-arm entries has reached statistical significance
(F(4,27)¼ 3.13, p¼ 0.031) (Figure 3b), Dunnett’s test
pointed to the anxiolytic influence of diazepam (p¼ 0.038)
and SH-053-S-CH3 dosed at 30 mg/kg (p¼ 0.049). The
influence on the percentage of time on open arms also was
significant (F(4,27)¼ 2.75, p¼ 0.049) (Figure 3c), but post
hoc testing did not detect a significant effect of any single
treatment.
SH-053-S-CH3-20F. Activity-related parameters: Statistical
evaluation by ANOVA did not show significant influences
of treatment on closed-arm entries, total-arm entries or total
distance travelled ((F(4,45)¼ 1.29, p¼ 0.290), (F(4,45)¼ 0.13,
p¼ 0.969), and (F(4,45)¼ 0.25, p¼ 0.911), respectively).
Anxiety-related parameters (Figure 4): Although the
influence of treatment on distance travelled in open arms
was not significant (F(4,45)¼ 1.92, p¼ 0.124) (Figure 4a),
the overall effect on the percentage of open arm entries
(Figure 4b) and the percentage of time on open arms
(Figure 4c) has reached statistical significance ((F(4,45)¼
2.94, p¼ 0.031) and (F(4,45)¼ 2.92, p¼ 0.031), respectively).
For both of these parameters, post hoc testing revealed the
equivalent influence of diazepam and SH-053-S-CH3 dosed at
30 mg/kg (p values 0.018 for the percentage of open-arm
entries and 0.017 for the percentage of time on open arms).
SH-053-R-CH3. When tested at doses up to 30 mg/kg, SH-
053-R-CH3 failed to induce any significant change of the
measured EPM parameters (data not shown).
Locomotor activity assay. Whole chamber activity: An
ANOVA showed a significant effect of treatment on total
distance travelled during 45 min of monitoring
(F(4,31)¼ 3.86, po0.001) (Figure 5, whole bars). According
to Dunnett’s test, the activity-decreasing effect of all four
tested compounds (diazepam 1.25 mg/kg, SH-053-S-CH3,
SH-053-S-CH3-20F and SH-053-R-CH3 at 30 mg/kg each)
was significant related to solvent. When the ANOVA was
applied on the 5 min intervals of travelled distance
(Figure 6), it turned out that locomotor activity was
significantly depressed in the time period 5–20 min (SH-
053-S-CH3 30 mg/kg, SH-053-S-CH3-20F 30 mg/kg, and
SH-053-R-CH3 30 mg/kg), whereas diazepam 1.25 mg/kg
decreased locomotion in the period 5–15 min.
Central/peripheral distance: An ANOVA showed a sig-
nificant effect of treatment on distance travelled in the
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Figure 2 Concentration–effect curves for SH-053-S-CH3 (a) and SH-
053-R-CH3 (b) on a1b3g2, a2b3g2, a3b3g2, and a5b3g2 GABAA receptors,
using an EC3 GABA concentration. Data points represent means7SEM
from at least four oocytes fromX2 batches. A concentration of 1 mM SH-
053-S-CH3 resulted in 12677, 216713, 207724 and 297711% of
control current (at GABA EC3) in a1b3g2, a2b3g2, a3b3g2, and a5b3g2
receptors, respectively. A concentration of 1 mM SH-053-R-CH3 resulted in
12477, 12575, 12075 and 186719% of control current in a1b3g2,
a2b3g2, a3b3g2, and a5b3g2, respectively. All these values were significantly
different from those of the respective control currents (po0.01, Student’s
t-test). For comparison, 1mM of diazepam (which in contrast to 1 mM
of SH-053-S-CH3 and SH-053-R-CH3 produces maximal stimulation of
GABA EC3 current) resulted in 345754, 508758, 7497107 and
420730% of control current for a1b3g2, a2b3g2, a3b3g2, and a5b3g2
receptors, respectively.
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monitoring (F(4,31)¼ 2.73, p¼ 0.047) (Figure 5, hatched
bars). The respective p values for diazepam 1.25 mg/kg,
SH-053-S-CH3 30 mg/kg, SH-053-S-CH3-20F 30 mg/kg, and
SH-053-R-CH3 30 mg/kg were 0.491, 0.029, 0.067, and 0.207,
related to solvent. According to ANOVA, the influence of
treatment on activity in peripheral parts of the chamber
(Figure 5, open bars) was more distinct: F(4.31)¼ 3.59,
p¼ 0.016; all the four treatments significantly decreased
activity when related to control by Dunnett’s test.
Rotarod test: When one monitors the influence on rotarod
performance as a quantal phenomenon (ie all or none
effect), the minimal incapacitating doses of SH-053-S-CH3
and SH-053-S-CH3-20F were 200 mg/kg for both substances.
The median incapacitating doses of diazepam, SH-053-
S-CH3, and SH-053-S-CH3-20F were 2.99, 213.67, and
218.80 mg/kg, respectively. Due to the shortage of sub-

































































Figure 3 The effects of diazepam (1.25 mg/kg) and SH-053-S-CH3
(10, 20 and 30 mg/kg) on the (a) distance travelled on open arms, (b)
percentage of entries in open arms and (c) percentage of time spent on
open arms of the EPM. Number of animals per treatment (for SOL through



































































Figure 4 The effects of diazepam (1.25 mg/kg) and SH-053-S-CH3-20F
(10, 20 and 30 mg/kg, designated as S-CH3-20F) on the (a) distance
travelled on open arms, (b) percentage of entries in open arms and
(c) percentage of time spent on open arms of the EPM. Number of animals
per treatment (for SOL through SH-053-S-CH3-20F 30 mg/kg) was 10.
*po0.05 compared to solvent (SOL) group.
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was not found; at doses up to 100 mg/kg it did not induce
any manifest incapacitation in this test.
DISCUSSION
The present experiments demonstrated the anxiolytic
potential of two newly synthesized compounds functionally
selective for a2-, a3-, and a5-containing GABAA receptors,
SH-053-S-CH3, and SH-053-S-CH3-20F, which is mainly
devoid of ataxic, but not of sedative actions characteristic of
nonselective BZs. Furthermore, a stereoisomer of SH-053-S-
CH3 functionally selective for GABAA receptors containing
the a5 subunit, SH-053-R-CH3, exerted in the locomotor
activity paradigm a significant hypolocomotor effect
comparable to diazepam, without observable anti-anxiety
or ataxic activity in the EPM, and rotarod test, respectively.
These findings were somewhat unexpected, since both
motor incoordination and sedation have been ascribed to
the a1 subunit-mediated action of diazepam (Rudolph et al,
1999; McKernan et al, 2000). Hence, either these three
compounds were not silent at the a1 subtype when dosed at
30 mg/kg, or some non-a1-subunit-containing receptors
contribute to the hypolocomotor action of BZ site agonists.
Although the absence of occupancy data for distinct
receptor subtypes precludes drawing firm conclusions, high
minimal incapacitating doses of the present functionally
selective ligands in the rotarod test could be seen as indirect
evidence for lack of involvement of GABAA receptors
containing the a1 subunit in behavioral actions of 30 mg/kg
doses. Specifically, diazepam-induced loss of motor co-
ordination in the rotarod test was linked to the a1 subunit
(Crestani et al, 2000; McKernan et al, 2000), and the
sevenfold differences in effective doses of SH-053-S-CH3
and SH-053-S-CH3-20F in rotarod vs SLA test could hardly
exist if substantial modulation at a1 subunit containing
GABAA receptors were attained already at 30 mg/kg.
However, there may exist marked differences in fractional
occupancy of GABAA receptors containing the a1 subunit
needed for producing behavioral effects of a BZ site agonist
in these two tests, meaning that low-to-moderate modula-
tion at such receptors is sufficient for eliciting sedative, but
not rotarod–incapacitating, action (cf. Facklam et al, 1992).
Nevertheless, the latter explanation is not highly probable
for the tested ligands with very low efficacies at a1-
containing subtypes. Namely, even the preferential a1
subunit-selective agonist, zolpidem, does not possess more
than 4.3 and 2.5 times greater potency to decrease
locomotor activity compared to rotarod impairment in rats
and mice, respectively (Sanger et al, 1996), whereas non-
subtype-selective agonists, such as diazepam, may be even
more potent in exerting rotarod impairment than locomo-
tor hypoactivity (Savic´ et al, 2003).
In its broadest sense, sedation involves decreased
psychomotor and cognitive performance, and in most
instances it is considered an adverse effect of psychotropic
drugs, which should be avoided. In animals, the psycho-
motor component is most frequently studied (Bourin and
Briley, 2004), and measurement of motor activity in rodents
represents a standard behavioral assay for testing the
sedative potential of drugs (Vogel, 2002). In fact, sensitivity
of preclinical tests for discerning the sedative potential of a
drug is of paramount importance; several BZ site partial
agonists developed as putative low-sedative anxiolytics have
nevertheless appeared to be incapacitating when subse-
quently tested in humans (Whiting, 2006). In support of the
sensitivity of the standard SLA test used in the present
study, Dailly et al (2002) observed a sedative effect of
diazepam (1 mg/kg i.p.) in the actimeter, but not in the
light–dark test of anxiety, which also measured locomotor
activity of mice. In accordance, SH-053-S-CH3, SH-053-20F-
S-CH3, and SH-053-R-CH3, all dosed at 30 mg/kg, exerted a
statistically significant depression of locomotion in the SLA





























Figure 5 The effects of diazepam (1.25 mg/kg), SH-053-S-CH3 (30 mg/
kg), SH-053-S-CH3-20F (30 mg/kg, designated as SH-053-S-20F) and SH-
053-R-CH3 (30 mg/kg) on distance travelled in the central (hatched bars)
and peripheral (open bars) zone of the activity chamber during 45 min of
recording (total activity corresponds to the height of the whole bar).
*po0.05 compared to solvent (SOL) group. Number of animals per
treatment (Figures 5 and 6) for SOL through SH-053-S-CH3-20F 30 mg/kg
was 8, and 4 for SH-053-R-CH3.
Time (min)


































Figure 6 The effects of diazepam (1.25 mg/kg), SH-053-S-CH3 (30 mg/
kg), SH-053-S-CH3-20F (30 mg/kg) and SH-053-R-CH3 (30 mg/kg) on the
distance travelled in 5 min intervals in the activity assay. *po0.05 compared
to solvent (SOL) group.
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activity parameters in the EPM (closed-arm entries and total
distance travelled), if any, was far from significant. It should
be emphasized that the hypolocomotor influence in the SLA
test is also evident when separately analyzing activity in the
peripheral zone of the chamber. Hence, the observed motor
depressant effects of the tested ligands were not dependent
on central zone activity, which is confounded by influences
on emotional reactivity, that is, anxiety, and could be seen
as a pure measure of sedation (cf. Savic´ et al, 2006). These
results further support the routine use of the SLA test
(Bourin and Briley, 2004; Vogel, 2002) in efforts to predict
clinical sedation.
On the other hand, it is noticeable that standard studies of
motor activity, which form the very basis of knowledge of
drug effects on behavior (Kelley, 1993), were not employed
for characterization of recently reported putative anxiose-
lective compounds (Atack et al, 2006c; Jennings et al, 2006;
Griebel et al, 2001; Russell et al, 2006). Jennings et al (2006)
reported on an a2/a3-BZ site-selective ligand from the class
of imidazo[1,2-b][1,2,4]triazines with anxiolytic activity in
the rat EPM test at the dose of 1 mg/kg, which showed no
motor incapacitation in the mouse rotarod test at doses up
to 30 mg/kg. A close congener of that compound was
anxiolytic in the rat EPM test at 3 mg/kg, whereas it showed
no significant activity in a surrogate assay of sedation
(chain-pulling test in rats) and in the mouse rotarod test
when tested in doses up to 10 mg/kg; reportedly, this
compound was chosen as a clinical candidate (Russell et al,
2006). Similarly, a 1,2,4-triazolo[4,3-b]pyridazine, TPA023,
exerted anxiolytic-like activity in the rat EPM and fear-
potentiated startle tests at the dose of 1 mg/kg as well as in
the assay of conditioned suppression of drinking at 3 mg/kg,
whereas, at doses up to 30 mg/kg, it did not significantly
affect behavior of rats in the chain-pulling test nor rotarod
performance of mice (Atack et al, 2006c). However, the
same experimental group, when testing pagoclone, detected
sedative action of this BZ site agonist dosed at 1 mg/kg in
the chain-pulling test, while already at 0.3 mg/kg in the SLA
test (Atack et al, 2006b). The very high dose (10 mg/kg) of
diazepam used as the active control in the chain-pulling test
(Atack et al, 2006b) additionally supports the view of
superior sensitivity of the standard SLA test.
From these reasons, it is difficult to compare behavioral
profiles of the compounds described in the present paper
with findings from the above-cited studies. Evidently, all
three newly synthesized BZ site ligands could have acted
through the a5 subtype-containing GABAA receptors, one of
them (SH-053-R-CH3) as an essentially subtype-selective
ligand. There exist data that support the possibility of
substantial motor manifestations of a5-containing GABAA
receptor modulation, besides the indirect consequences
brought on by the effects on learning and memory
processes, where pertinent (Collinson et al, 2002; Crestani
et al, 2002). Somatic and preganglionic motoneurons in the
spinal cord exhibit a moderate-to-strong staining for the a5
subunit (Bohlhalter et al, 1996), whereas the knock-in mice
harboring the a5 subunit insensitive to diazepam are
refractory to development of tolerance to the sedative effect
of diazepam dosed subchronically, presumably due to a
downregulation of a5 subunits in the dentate gyrus (van
Rijnsoever et al, 2004). Hence, we hypothesize that any
locomotor activity changes induced by ligands possessing a
substantial a5-efficacy may be, at least partly, contributed
by modulation at GABAA receptors containing this subunit.
Nevertheless, as a caveat to all studies examining sedation,
it should be remembered that a decrease in automatically
measured locomotor activity can be due to a variety of
causes other than sedation, including the occurrence of
stereotyped behavior, motor impairments or pain (Porsolt
et al, 1993). In addition, particular caution is needed when
transposing in vitro data to the in vivo conditions. Atack
et al (2006a) reported on substantial decrease of the a5
subtype-binding selectivity of the BZ site inverse agonist
RY-080 (Liu et al, 1995) when binding was tested in vivo;
since RY-080 exerted appreciable inverse agonist-efficacy at
the a1-containing GABAA receptors (Atack et al, 2006a),
interpretation of behavioral actions of such functionally
nonselective ligands is especially hindered. To dissect these
overlaps in activity and uncertainties, much is expected
from screening of newer BZ site ligands in the future, which
will be still more functionally selective than those presented
in this work.
In conclusion, the present results confirm the highly
diminished ataxic potential of BZ site agonists devoid of a1
subunit-mediated effects. Anti-anxiety activity of such
ligands remains preserved, whereas the confounding seda-
tion stays observable, and may be partly dependent on the
a5-containing GABAA receptors. Hence, it could be of
importance to avoid substantial potentiation through the a5
subunits by the candidate anxioselective anxiolytics, if the
clinical sedation is to be prevented.
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